This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Bladder Cancer
Conferences
Recent Abstracts
AUA 2024: Major Complications and Adverse Events of SpaceOAR Hydrogel: An Analysis of the Manufacturer and User Facility Device Experience Database
May 6, 2024
AUA 2024: Cancer Control Rates in Adequate Versus Inadequate Treatment with Adjuvant Immunotherapy Instillations with BCG
May 6, 2024
AUA 2024: Review of SpaceOAR Complications in The MAUDE Database with Focus on Rectal Wall Infiltration
May 6, 2024
AUA 2024: Survey on Clinical Practice Patterns in the United States for Using Intravesical Chemotherapy in the Management of BCG Unresponsive Non-Muscle Invasive Bladder Cancer
May 6, 2024
AUA 2024: First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–muscle-Invasive Bladder Cancer with Select FGFR Alterations
May 6, 2024
AUA 2024: Temporal and Regional Patterns of Prostate Cancer Positron Emission Tomography Imaging Among Commercial Insurance Beneficiaries in the United States
May 6, 2024
AUA 2024: Efficacy of Nadofaragene Firadenovec-vncg for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial
May 6, 2024
AUA 2024: PSMA-PET Guided Metastasis Directed Therapy for Oligometastatic Prostate Cancer
May 6, 2024
AUA 2024: Exploring Recurrence After Initial Response to UGN-101 Induction in Expanded Settings
May 6, 2024
AUA 2024: Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis
May 6, 2024
AUA 2024: Genetic Testing in Prostate Cancer: The Role of the Urologists
May 6, 2024
AUA 2024: BOND-003- Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 6, 2024
AUA 2024: Prostate Cancer: Dissemination and Availability of Minimally Invasive Treatments to Underserved Populations
May 6, 2024
AUA 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor
May 6, 2024
AUA 2024: SSANTROP (APRO07-2022): A Phase II Prospective, Open-Label, Multi-Center, Single Arm Study of Sasanlimab + Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
May 6, 2024
AUA 2024: QUILT-2.005: A Comparison of Intravesical BCG in Combination with the IL-15 Superagonist N-803 to BCG Alone in Patients with BCG-Naïve NMIBC
May 6, 2024
AUA 2024: Sequential Endoluminal Gemcitabine and Docetaxel Versus Bacillus Calmette–Guérin for the Treatment of High-Grade Upper Tract Urothelial Carcinoma
May 5, 2024
AUA 2024: Longitudinal Follow Up of Multicenter Study of UGN-101 for Upper Tract Urothelial Cancer
May 5, 2024
AUA 2024: Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients with Biochemical Recurrent Prostate Cancer: A Retrospective Cohort Study
May 5, 2024
AUA 2024: MoonRISe-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Delivery System, Versus Intravesical Chemotherapy in Patients with Intermediate-Risk Non–Muscle-Invasive Bladder Cancer with Susceptible FGFR Alterations
May 5, 2024
Page 22 of 584
Start
Prev
17
18
19
20
21
22
23
24
25
26
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free